As a result, HRAS mutant squamous- and head and neck cancers, NRAS mutant novel melanomas or myelomonocytic leukemia and KRAS mutant colorectal cancers could be developed upon BRAF inhibitor therapies (38, 39, 40). Here, BRAF is linked to colorectal cancer.